When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-025-09333-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Xiaofen Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, No. 628, Zhenyuan Road, Guangming District, Shenzhen, 518107, China.…. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: To study the safety of resuming antitumor therapy in tumor patients infected with COVID-19. METHODS: We collected the clinical information of patients with tumors who were infected with COVID-19 and resume antitumor therapy between December 2022 and June 2023. Information about antitumor therapy, COVID-19-related symptoms, laboratory tests, antitumor therapy-related adverse events (AEs), and re-infection with COVID-19 were recorded. Primary endpoints included the incidence of AEs and re-infection of COVID-19. The secondary endpoints included the incidence and duration of COVID-19 related symptoms. RESULTS: The most common COVID-19 symptoms were fever (39.5%), cough (37.2%), and fatigue (44.2%). Most patients' symptoms lasted no more than a week Two patients were re-infected with COVID-19. All-grade AEs with an incidence rate > 10% included anemia, increased gamma-glutamyl transferase (GGT), anorexia, neutropenia, hypocalcemia, leukopenia, thrombocytopenia, increased alanine aminotransferase, increased aspartate aminotransferase, hypokalemia, hyponatremia, and nausea. Grade 3-4 AEs with an incidence rate higher than 5% included anemia, neutropenia, leukopenia, thrombocytopenia, anorexia, and vomiting. The incidence of AEs before and after COVID-19 infection did not show a significant difference. CONCLUSION: Resuming antitumor therapy early after SARS-CoV-2 test turned negative did not increase antitumor therapy-related AEs or the incidence of re-infection in COVID-19 infection patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, No. 628, Zhenyuan Road, Guangming District, Shenzhen, 518107, China. panxf8@mail.sysu.edu.cn.
- Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, No. 628, Zhenyuan Road, Guangming District, Shenzhen, 518107, China.
- Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, No. 628, Zhenyuan Road, Guangming District, Shenzhen, 518107, China. wangb76@mail.sysu.edu.cn.
Zitieren
APA
Pan, X., Zhu, M., Huang, G., Li, X., Liao, J., Huang, S., & Wang, B. (2025). When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-09333-9
Vancouver
Pan X, Zhu M, Huang G, Li X, Liao J, Huang S, et al. When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-09333-9
BibTeX
@article{Pan2025,
author = {Pan, Xiaofen and Zhu, Mengyuan and Huang, Guihao and Li, Xueying and Liao, Jiehao and Huang, Shan and Wang, Bo},
title = {When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-025-09333-9}
}
EUVIMED